Coherus Ranibizumab Sales Quadruple Thanks To Q-Code Boost
Firm Also Looking At More Adalimumab PBM, Distribution Deals
Coherus BioSciences has welcomed an uplift of sales for its ranibizumab biosimilar, as well as discussing its efforts to reinvigorate its pegfilgrastim biosimilar franchise, during the company’s second-quarter earnings call.
